Entellus Latera Hero

Entellus Medical Announces 24 Month Data on Latera Nasal Implant

Posted on October 30, 2017 by Medtech[y] Staff


Entellus CEO, Bob White, announced the 24 month data from its first-in-human study of the Latera absorbable nasal implant from Spirox

Latera is a product developed by Spirox, which was acquired earlier this year by Entellus Medical.

Key findings of the study include:

  • Continuing, significant NOSE score reduction at all time points, averaging 63.4%, 56.2%, 52%, 52.5% and 57.7% at 3, 6, 12, 18 and 24 months, respectively (p<0.001)
  • No adverse change in cosmetic appearance at 24 months post procedure
  • Short learning curve for physicians adopting the technology

"We are pleased to see continued evidence reinforcing that Latera is a safe and effective treatment option for patients with NVC, with the potential to become standard of care,” said 

Robert White, President and Chief Executive Officer of Entellus Medical. “We look forward to increasing access to Latera for ENT physicians and plastic surgeons seeking a treatment option for their nasal obstruction patients.”

“These newly released data from our study have met our pre-defined criteria for success including symptom relief without negatively affecting appearance,” stated Dr. 

Marion San Nicolo, M.D., University Clinic of Munich, LMU and lead enroller in the study stated.  “In addition, patients who benefitted from Latera experienced continued symptom relief after the implant had absorbed.”

What is Latera?

Entellus believes the market for patient's with compromised nasal valves is significant.

Nasal Valve Compromise
Entellus Medical Investor Presentation

We should get a better understanding of Latera's revenue after Entellus releases Q3 earnings on November 1.